This study is looking at how men and women with cannabis use disorder (CUD) respond differently to THC, the main active ingredient in cannabis. You might be able to join if you are 21-45 years old, have CUD, and use cannabis at least four days a week. The study will test oral dronabinol capsules (a form of THC) against a placebo (an inactive pill). Researchers will measure brain chemicals (glutamate) and brain activity related to reward anticipation to see if there are differences between sexes after taking dronabinol. The goal is to understand how THC affects the brain's reward system in people with CUD, and if these effects differ between men and women. The study is currently recruiting participants.

Study design

This is an interventional study with 40 planned participants. It compares the effects of dronabinol to a placebo.

What's involved

You will complete two study sessions where you receive either dronabinol or a placebo. During these sessions, you will undergo brain imaging tests.

Compensation

Not stated in the trial record.

Follow-up

Brain chemical levels are measured at 2 hours post-dose, and brain activity is measured at 3 hours post-dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.